The inhibition of gonadotropin secretion in childrcn with central precocious puberty treatcd with LH-RIi analogues results in suppression of the pubertal devclopment, including growth velocity. In some paticnts, a marked slowing of growth is observed. To test whether this is related to inhibision of GH secrction, we performed a clonidine test (150 mcg/m p.0.) in 9 girls with central precocious puberty (age range: 4 4/12 to 11 8/12 yrs) treated with D-TRP-6-LM-RH, a supcractive LH-RH analogue, 6 by daily s.c. injections of an acqueous preparation, and 3 by monthly i.m. injections of a depot preparation (DecapeptylFerring). The daily dose ranged from 1.5 to 3 mcglkglday and thc treatment periods were from 10 to 60 months. In all patients a normal GA response was found, by a peak value of 18 nglml or higher. In all, gonadotropin suppression was confirmed by a concomitant i.v. LH-RH test. These data show that GI1 reserve is not affcctcd by the LH-RH analogue therapy and cannot be implicated in the slowing of growth, which is probably due to lack of sex hormones.
It is assumed that idiopathic central precocious puberty in girls is progressive and leads to sexual maturity. Its natural course, however, is not well defined. Four girls presented with breast enlargement (B3) at age 4.0-6.0 yrs and have been followed for up to 3.5 yrs. All had normal CT brain scans. Stimulation of LH and FSH by LHRH was excessive for age in all. Estradiol (E2) was 62-122 pmol/L. Bone age was advanced by 1.8 and 2.8 yrs in 2 girls and progressed rapidly in all. Ultrasound visualized follicular ovarian cysts in 3/4. In 2 girls, E2 fell slowly to levels around 40 pmol/L and breast enlargement decreased 1.0 to 1.5 yr after the initial work-up. The other 2 girls showed a regression of clinical signs with normalization of E2 levels after 6 and 10 months, respectively. Another 6 months later, puberty was progressing clinically and biochemically in both. As illustrated, central precocious puberty can be transient and regressing, or fluctuating in its course. This has to be considered when new drugs to control precocious puberty are evaluated for their effectiveness. 
I n t h e a d u l t dogs t r e a t e d f o r 15 weeks spermatogenesis was i n h i b i t e d d u r i n g therapy and recover e d 90 days a f t e r t h e l a s t i n j e c t i o n . A one-year treatment was s t a r t e d i n 3 adolescent dogs j u s t b e f o r e completion o f puberty.
LH l e v e l (ng/ml , fcsem) decreased from 4.6 + 0.6 t o 1.2 t 0.1 on day 21 (p<0.05) and became undetectable beyond t h e 5 t h i n j e c t i o n .
Normal o r h i g h l e v e l s were recovered 60 days a f t e r t h e l a s t i n j e c t i o n . Mean t e s t o s t e r o n e l e v e l (ng/ml) was 1.6 t 0 . 2 i n i t i a ll y , undetectable beyond t h e 5 t h i n j e c t i o n and 1 . 3 f 0 . 3 s i x t y days a f t e r t h e l a s t i n j e c t i o n . H i s t o l o g y o f t h e r i g h t t e s t i s on day 371 showed spermatogonia i n a l l tubes, spermatocytes I i n 5 t o 57% o f tubes and absence o f more mature c e l l s . I n i t i a l l y , no spermatozoa were present i n e j a c u l a t e s , b u t i n 2 dogs sperm c e l l s were present from days 56 t o 77 and 64 t o 105 r e s p e c t i v e l y , d i s a p peared t h e r e a f t e r and reappared 92 days a f t e r t h e l a s t i n j e c t i o n . No sperm c e l l s were found i n t h e 3 r d dog throughout t h e study. T h i s work shows t h a t LRH-M induces a regression o f spermatogenes i s i n adolescent dogs and t h a t recovery occurs a f t e r treatment.
To d e t e c t a n e a r l y h y p o t h a l a m i c i m p a i r e m e n t i n 33 c h i l d r e n u i t h i d i o p a t h i c p r e c o c i o u s p u b e r t y u e r e v i e u e d t h e i r f e t a l and m a t e r n a l g r a v i d i c h i s t o r y . F o r t h ye i g h t p e r c e n t o f t h e m o t h e r s h a d t h r e a t e n e d a b o r t i o n i n t h e 1 s t t r i m e s t e r ( 1 6 c a s e s ) o r g e s t o s i s ( 3 c a s e s ) . Most o f t h e uomen ( 1 3 / 1 9 ) " e r e t r e a t e d u i t h p r o g es t i n s a l o n e o r i n c o m b i n a t i o n w i t h e s t r o g e n s ; and i n one a d d i t i o n a l m o t h e r p r o g es t e r o n e was g i v e n p r o p h y l a c t i c a l l y f o r a h i s t o r y o f h a b i t u a l a b o r t i o n . The h o r n on a l t h e r a p y u a s g i v e n a t d i f f e r e n t doses and f o r d i f f e r e n t p e r i o d s o f t i m e . The a s s o c i a t i o n o f m a t e r n a l g r a v i d i c p a t h o l o g y -m a i n l y t h r e a t e n e d a b o r t i o n -and i d i o p a t h i c p r e c o c i o u s p u b e r t y seems n o t t o be f o r t u i t o u s , s i n c e t h e i n c i d e n c e o f t h r e a t e n e d a b o r t i o n i n o u r p o p u l a t i o n i s 4. 5%
o f t h e p r e g n a n c i e s c a r r i e d o u t . 
We t h e r e f o r e i n d i c a t e t h e p o s s i b l e r o l e o f hormonal t h e r a p y . more t h a n g r a v i d i c p a t h o l o g y i t s e l f i n d e t e r m i n i n g t h e e a r l y awakening of t h e h y p o t h a l a m i c c e n t e r s .

F i n a l l y i t i s i n t e r e s t i n g t o n o t e t h e d i f f e r e n t mean age o f t h e o n s e t o f p u b e r t y i n g i r l s u i t h and w i t h o u t q r a v i d i c p a t h o l o g y o r t r e
URINARY EXCRETION OF BUSERELIN ( 8 ) DURING THERAPY OF CENTRAL PRECOCIOUS PUBERTY (PP). A MULTICENTER STUDY.
128 12 hrs urine collections were made in patients presenting with central PP receiving the GnRH agonist B, either subcutaneously (SC) (13 girls and 5 boys) or intranasally (IN) ( 7 girls and 4 boys). Centers from Belgium, France, Germany, Holland and Switzerland participated in this study. Urinary excretion of inmunoreactive B and B metabolites measured after SC administration of 20pg/kg once a day in 14 girls with good control was 88.5' 7.5pg (mean ' SEM) during the first 12hrs and 6.0'1.2ug during the following 12hrs. Mean E2 levels under therapy was 8.9i0.9pglml. 6 girls receiving 20pg/kg t.i.d. has an excretion of 91.5'8.7 and 89.5?9.2ug/12hrs, respectively. Two girls with poor control showed excretion levels similar to those with good control. In the 5 boys treated SC, similar levels to those measured in girls were found. One of them remained resistant (T>3.8ng/ml). In the 5 girls and 4 boys receiving IN 28.7'1.5pg/day of B, urinary excretion was 4.3' 0.9pg/12hrs during daytime and 2.9t0.8pg during nighttime. Clini- 
